NCT06463457 2026-03-09
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT05617885 2026-02-27
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04558866 2026-02-12
ExBAT
Latin American Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06627530 2026-02-11
COAction
Brazilian Clinical Research Institute
Phase 4 Active not recruiting
NCT06734130 2026-01-21
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04025372 2025-12-15
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT04335682 2025-11-04
ARACOG
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
NCT04319783 2025-08-21
DECREASE
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT05694819 2025-05-22
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT04136353 2023-07-28
DASL-HiCaP
University of Sydney
Phase 3 Active not recruiting